Research progress of cytokine release syndrome related to CAR-T immunotherapy

doi:10.3760/cma.j.cn371439-20221203-00075

Abstract

Abstract:

Chimeric antigen receptor T-cell （CAR-T） immunotherapy is one of the new models of tumor targeted therapy. However，the presence of cytokine release syndrome （CRS） after CAR-T infusion is a key obstacle limiting its therapeutic effects. Macrophage activation and pyrosis of target tumor cells can trigger the release of interleukin-6 and other inflammatory factors，and excessive inflammatory factors can lead to excessive activation of endothelial cells，which is a key molecular mechanism for the escalation of CRS and the occurrence of serious adverse events. Intervention in multiple stages of cytokine production and structural optimization of chimeric antigen receptor molecules are effective strategies to reduce CRS.

Key words: Cytokine release syndrome, Macrophages, Interleukin-6, Chimeric antigen receptor T-cell

Zhang Li, Xiang Zhuo, Wang Qiang, Bi Jingwang. Research progress of cytokine release syndrome related to CAR-T immunotherapy[J]. Journal of International Oncology, 2023, 50(6): 377-381.

References 47

[1]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. DOI: 10.1016/j.bbmt.2018.12.758. doi: 10.1016/j.bbmt.2018.12.758
[2]	Yan Z, Zhang H, Cao J, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment[J]. Front Immunol, 2021, 12: 611366. DOI: 10.3389/fimmu.2021.611366. doi: 10.3389/fimmu.2021.611366
[3]	Lei W, Xie M, Jiang Q, et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis[J]. Cancers (Basel), 2021, 13(15): 3912. DOI: 10.3390/cancers13153912. doi: 10.3390/cancers13153912
[4]	Chen X, Li P, Tian B, et al. Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors[J]. Front Immunol, 2022, 13: 1079181. DOI: 10.3389/fimmu.2022.1079181. doi: 10.3389/fimmu.2022.1079181
[5]	Hao Z, Li R, Meng L, et al. Macrophage, the potential key mediator in CAR-T related CRS[J]. Exp Hematol Oncol, 2020, 9: 15. DOI: 10.1186/s40164-020-00171-5. doi: 10.1186/s40164-020-00171-5 pmid: 32665874
[6]	Guo H, Qian L, Cui J. Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome[J]. Cancer Biol Med, 2021, 19(3): 333-342. DOI: 10.20892/j.issn.2095-3941.2021.0087. doi: 10.20892/j.issn.2095-3941.2021.0087
[7]	Yang W, Bai X, Luan X, et al. Delicate regulation of IL-1β-mediated inflammation by cyclophilin A[J]. Cell Rep, 2022, 38(11): 110513. DOI: 10.1016/j.celrep.2022.110513. doi: 10.1016/j.celrep.2022.110513
[8]	Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity[J]. Immunity, 2019, 50(4): 778-795. DOI: 10.1016/j.immuni.2019.03.012. doi: S1074-7613(19)30129-3 pmid: 30995499
[9]	Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies[J]. Blood, 2020, 135(1): 17-27. DOI: 10.1182/blood.2019000017. doi: 10.1182/blood.2019000017 pmid: 31697824
[10]	Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood, 2019, 133(7): 697-709. DOI: 10.1182/blood-2018-10-881722. doi: 10.1182/blood-2018-10-881722 pmid: 30463995
[11]	Ingelfinger F, De Feo D, Becher B. GM-CSF: master regulator of the T cell-phagocyte interface during inflammation[J]. Semin Immunol, 2021, 54: 101518. DOI: 10.1016/j.smim.2021.101518. doi: 10.1016/j.smim.2021.101518
[12]	Sachdeva M, Duchateau P, Depil S, et al. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators[J]. J Biol Chem, 2019, 294(14): 5430-5437. DOI: 10.1074/jbc.AC119.007558. doi: 10.1074/jbc.AC119.007558 pmid: 30804212
[13]	Flynn CM, Garbers Y, Lokau J, et al. Activation of Toll-like receptor 2 (TLR2) induces interleukin-6 trans-signaling[J]. Sci Rep, 2019, 9(1): 7306. DOI: 10.1038/s41598-019-43617-5. doi: 10.1038/s41598-019-43617-5 pmid: 31086276
[14]	RIddell SR. Adrenaline fuels a cytokine storm during immunotherapy[J]. Nature, 2018, 564(7735): 194-196. DOI: 10.1038/d41586-018-07581-w. doi: 10.1038/d41586-018-07581-w
[15]	Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies[J]. J Exp Clin Cancer Res, 2021, 40(1): 367. DOI: 10.1186/s13046-021-02148-6. doi: 10.1186/s13046-021-02148-6
[16]	Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation[J]. Nat Rev Immunol, 2020, 20(3): 143-157. DOI: 10.1038/s41577-019-0228-2. doi: 10.1038/s41577-019-0228-2 pmid: 31690840
[17]	Liu Y, Fang Y, Chen X, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome[J]. Sci Immunol, 2020, 5(43): eaax7969. DOI: 10.1126/sciimmunol.aax7969. doi: 10.1126/sciimmunol.aax7969
[18]	Wang C, Yang T, Xiao J, et al. NLRP3 inflammasome activation triggers gasdermin D-independent inflammation[J]. Sci Immunol, 2021, 6(64): eabj3859. DOI: 10.1126/sciimmunol.abj3859. doi: 10.1126/sciimmunol.abj3859
[19]	Huang Y, Li D, Zhang PF, et al. IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells[J]. FASEB J, 2020, 34(1): 1768-1782. DOI: 10.1096/fj.201901809R. doi: 10.1096/fj.201901809R pmid: 31914650
[20]	Fajgenbaum DC, June CH. Cytokine storm[J]. N Engl J Med, 2020, 383(23): 2255-2273. DOI: 10.1056/NEJMra2026131. doi: 10.1056/NEJMra2026131
[21]	Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. DOI: 10.1038/s41591-018-0036-4. doi: 10.1038/s41591-018-0036-4 pmid: 29808007
[22]	Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome[J]. Immunity, 2020, 52(5): 731-733. DOI: 10.1016/j.immuni.2020.04.003. doi: S1074-7613(20)30161-8 pmid: 32325025
[23]	Wang J, Doran J. The many faces of cytokine release syndrome-related coagulopathy[J]. Clin Hematol Int, 2021, 3(1): 3-12. DOI: 10.2991/chi.k.210117.001. doi: 10.2991/chi.k.210117.001
[24]	D'Alessandro E, Scaf B, Munts C, et al. Coagulation factor Xa induces proinflammatory responses in cardiac fibroblasts via activation of protease-activated receptor-1[J]. Cells, 2021, 10(11): 2958. DOI: 10.3390/cells10112958. doi: 10.3390/cells10112958
[25]	Shao M, Yu Q, Teng X, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase Ⅰ/Ⅱ clinical trial[J]. Bone Marrow Transplant, 2021, 56(7): 1642-1650. DOI: 10.1038/s41409-021-01226-9. doi: 10.1038/s41409-021-01226-9
[26]	Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages[J]. Nat Rev Immunol, 2020, 20(6): 355-362. DOI: 10.1038/s41577-020-0331-4. doi: 10.1038/s41577-020-0331-4 pmid: 32376901
[27]	Kang S, Tanaka T, Inoue H, et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome[J]. Proc Natl Acad Sci U S A, 2020, 117(36): 22351-22356. DOI: 10.1073/pnas.2010229117. doi: 10.1073/pnas.2010229117
[28]	Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome[J]. Oncologist, 2018, 23(8): 943-947. DOI: 10.1634/theoncologist.2018-0028. doi: 10.1634/theoncologist.2018-0028 pmid: 29622697
[29]	Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline[J]. J Clin Oncol, 2021, 39(35): 3978-3992. DOI: 10.1200/JCO.21.01992. doi: 10.1200/JCO.21.01992
[30]	Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol, 2022, 33(3): 259-275. DOI: 10.1016/j.annonc.2021.12.003. doi: 10.1016/j.annonc.2021.12.003
[31]	Caimi PF, Pacheco Sanchez G, Sharma A, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma[J]. Front Immunol, 2021, 12: 745320. DOI: 10.3389/fimmu.2021.745320. doi: 10.3389/fimmu.2021.745320
[32]	Myers RM, Kadauke S, Li Y, et al. Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL)[J]. Biol Blood Marrow Transplant, 2020, 26(3): S39. DOI: 10.1016/j.bbmt.2019.12.105. doi: 10.1016/j.bbmt.2019.12.105
[33]	Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma[J]. Br J Haematol, 2021, 194(4): 690-700. DOI: 10.1111/bjh.17527. doi: 10.1111/bjh.17527
[34]	Wang X, Qi Y, Li H, et al. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy[J]. Front Immunol, 2022, 13: 943004. DOI: 10.3389/fimmu.2022.943004. doi: 10.3389/fimmu.2022.943004
[35]	Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells[J]. Blood, 2019, 133(20): 2212-2221. DOI: 10.1182/blood-2018-12-893396. doi: 10.1182/blood-2018-12-893396 pmid: 30808634
[36]	Wehrli M, Gallagher K, Chen YB, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)[J]. J Immunother Cancer, 2022, 10(1): e003847. DOI: 10.1136/jitc-2021-003847. doi: 10.1136/jitc-2021-003847
[37]	Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still's disease[J]. Rheumatology (Oxford), 2019, 58(Suppl 6): vi9-vi22. DOI: 10.1093/rheumatology/kez350. doi: 10.1093/rheumatology/kez350
[38]	Temesgen Z, Assi M, Shweta FNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study[J]. Mayo Clin Proc, 2020, 95(11): 2382-2394. DOI: 10.1016/j.mayocp.2020.08.038. doi: 10.1016/j.mayocp.2020.08.038 pmid: 33153629
[39]	Huarte E, O'Connor RS, Peel MT, et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy[J]. Clin Cancer Res, 2020, 26(23): 6299-6309. DOI: 10.1158/1078-0432.CCR-20-1739. doi: 10.1158/1078-0432.CCR-20-1739 pmid: 32998963
[40]	Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells[J]. Sci Transl Med, 2019, 11(499): eaau5907. DOI: 10.1126/scitranslmed.aau5907. doi: 10.1126/scitranslmed.aau5907
[41]	Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia[J]. J Clin Oncol, 2021, 39(27): 3044-3055. DOI: 10.1200/JCO.20.03458. doi: 10.1200/JCO.20.03458
[42]	Davey AS, Call ME, Call MJ. The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities[J]. Cancers (Basel), 2020, 13(1): 38. DOI: 10.3390/cancers13010038. doi: 10.3390/cancers13010038
[43]	Alabanza L, Pegues M, Geldres C, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains[J]. Mol Ther, 2017, 25(11): 2452-2465. DOI: 10.1016/j.ymthe.2017.07.013. doi: S1525-0016(17)30354-4 pmid: 28807568
[44]	Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy[J]. Nat Med, 2019, 25(6): 947-953. DOI: 10.1038/s41591-019-0421-7. doi: 10.1038/s41591-019-0421-7 pmid: 31011207
[45]	Tan AHJ, Vinanica N, Campana D. Chimeric antigen receptor-T cells with cytokine neutralizing capacity[J]. Blood Adv, 2020, 4(7): 1419-1431. DOI: 10.1182/bloodadvances.2019001287. doi: 10.1182/bloodadvances.2019001287 pmid: 32271901
[46]	Feucht J, Sun J, Eyquem J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency[J]. Nat Med, 2019, 25(1): 82-88. DOI: 10.1038/s41591-018-0290-5. doi: 10.1038/s41591-018-0290-5 pmid: 30559421
[47]	Kang L, Tang X, Zhang J, et al. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes[J]. Exp Hematol Oncol, 2020, 9: 11. DOI: 10.1186/s40164-020-00166-2. doi: 10.1186/s40164-020-00166-2 pmid: 32523801